Estrella Immunopharma, Inc.
ESLA Nasdaq
SEC CIK 1844417
Follow Estrella Immunopharma
Weekly email: filings, results
Net income
−$7.4M
−53.8% vs same quarter last year
EPS, diluted
−$0.17
−30.8% vs same quarter last year
Operating cash flow
−$217.2K
+70.1% vs same quarter last year
Operating income
−$7.5M
−58.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$13.1M |
| FY24 | −$7.3M |
| FY23 | −$11.1M |
| FY22 | −$996.1K |
| FY21 | −$247.7K |
| FY20 | - |